Breaking News Instant updates and real-time market news.

REPH

Recro Pharma

$7.90

1.56 (24.61%)

07:44
04/04/19
04/04
07:44
04/04/19
07:44

Recro Pharma price target raised to $15 from $9 at Oppenheimer

Oppenheimer analyst Leland Gershell raised his price target for Recro Pharma to $15 from $9 to reflect the company's updated business plan. With its announced plan to restructure its Acute Care Segment, which should enable Recro Pharma to become cash flow positive in the second half of 2019 by virtue of its growing CDMO business, the analyst believes the company is taking rational steps toward rebuilding equity value following IV meloxicam's 2nd CRL. He reiterates an Outperform rating on the shares.

REPH Recro Pharma
$7.90

1.56 (24.61%)

03/25/19
PIPR
03/25/19
NO CHANGE
Target $9
PIPR
Overweight
Recro CRL disappointing, but don't ignore CDMO business, says Piper Jaffray
Piper Jaffray analyst David Amsellem lowered his price target for Recro Pharma to $9 from $12 after the company received a second Complete Response Letter from the FDA for its intravenous form of meloxicam for post-operative pain. What is clear from the CRL is that the agency has moved the goal posts on Recro, Amsellem tells investors in a research note. Two successful placebo-controlled studies along with a large safety data base, historically the standard by which agents for acute pain are evaluated, "does not pass muster in this case," says the analyst. As such, he would not be surprised to see Recro initiate a dispute resolution process. Though the latest CRL is "undoubtedly disappointing," the company's cash flows from its contract development and manufacturing organization segment are not fully appreciated at current share levels, argues Amsellem. He believes this should "provide a floor in the high-single digits per share at a minimum." The analyst reiterates an Overweight rating on Recro Pharma.
03/25/19
OPCO
03/25/19
NO CHANGE
Target $9
OPCO
Outperform
Recro Pharma price target lowered to $9 from $19 at Oppenheimer
Oppenheimer analyst Leland Gershell lowered his price target for Recro Pharma to $9 from $19 saying that a second CRL for IV meloxicam comes as a "surprising disappointment," as he had perceived the issues that held up initial approval as relatively minor and resolvable through further negotiation between the company and the FDA. Following this recent action, the analyst now lacks clarity on approval prospects as well as on how Recro Pharma will adequately address the agency's concerns. Gershell reiterates an Outperform rating on the shares.
03/25/19
ROTH
03/25/19
DOWNGRADE
ROTH
Neutral
Recro Pharma downgraded to Neutral from Buy at Roth Capital
03/25/19
03/25/19
DOWNGRADE
Target $7.5

Neutral
Recro Pharma downgraded to Neutral after IV Meloxicam CRL at Roth Capital
As previously reported, Roth Capital analyst Scott Henry downgraded Recro Pharma to Neutral from Buy after the FDA issued a CRL to the company with regards to the pain drug IV meloxicam. The analyst notes this was not expected given the unmet need for non-opioid pain relievers, and expects Recro Pharma to pursue dispute resolution. Additionally, Henry believes that the company needs to cut costs and pursue profitability with the CDMO business near-term. The analyst also lowered his price target on the shares to $7.50 from $15.

TODAY'S FREE FLY STORIES

XLNX

Xilinx

$139.79

2.66 (1.94%)

07:44
04/25/19
04/25
07:44
04/25/19
07:44
Downgrade
Xilinx rating change  »

Xilinx downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

CIGI

Colliers International

$69.14

-0.39 (-0.56%)

07:44
04/25/19
04/25
07:44
04/25/19
07:44
Hot Stocks
Colliers International acquires affiliate in Sweden »

Colliers International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 05

    Jun

ABBV

AbbVie

$78.71

0.06 (0.08%)

07:43
04/25/19
04/25
07:43
04/25/19
07:43
Earnings
AbbVie raises FY19 adj. EPS view to $8.73-$8.83 from $8.65-$8.75 »

FY19 consensus $8.69. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 28

    Apr

  • 03

    May

  • 03

    May

  • 04

    May

  • 18

    May

  • 31

    May

  • 05

    Jun

HAS

Hasbro

$103.18

2.84 (2.83%)

07:42
04/25/19
04/25
07:42
04/25/19
07:42
Downgrade
Hasbro rating change  »

Hasbro downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 29

    May

WAB

Wabtec

$76.57

-0.19 (-0.25%)

, GE

General Electric

$9.32

-0.025 (-0.27%)

07:42
04/25/19
04/25
07:42
04/25/19
07:42
Hot Stocks
Wabtec CEO Ray Betler to retire, Rafael Santana to succeed »

Wabtec (WAB) announced…

WAB

Wabtec

$76.57

-0.19 (-0.25%)

GE

General Electric

$9.32

-0.025 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

  • 08

    May

  • 08

    May

  • 21

    May

  • 29

    May

  • 05

    Jun

  • 05

    Jun

  • 13

    Nov

ABBV

AbbVie

$78.71

0.06 (0.08%)

07:42
04/25/19
04/25
07:42
04/25/19
07:42
Hot Stocks
Breaking Hot Stocks news story on AbbVie »

AbbVie raises FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 28

    Apr

  • 03

    May

  • 03

    May

  • 04

    May

  • 18

    May

  • 31

    May

  • 05

    Jun

ABBV

AbbVie

$78.71

0.06 (0.08%)

07:42
04/25/19
04/25
07:42
04/25/19
07:42
Earnings
AbbVie reports Q1 adjusted EPS $2.14, consensus $2.06 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 28

    Apr

  • 03

    May

  • 03

    May

  • 04

    May

  • 18

    May

  • 31

    May

  • 05

    Jun

HBAN

Huntington Bancshares

$13.75

-0.04 (-0.29%)

07:40
04/25/19
04/25
07:40
04/25/19
07:40
Earnings
Huntington Bancshares sees FY19 revenue up 4%-7%, consensus $4.76B »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

  • 31

    May

  • 29

    Aug

REPL

Replimune Group

$15.32

1 (6.98%)

07:40
04/25/19
04/25
07:40
04/25/19
07:40
Initiation
Replimune Group initiated  »

Replimune Group added to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALKS

Alkermes

$34.80

0.6 (1.75%)

07:40
04/25/19
04/25
07:40
04/25/19
07:40
Hot Stocks
Alkermes reports Q1 Vivitrol revenue $69.2M vs. $62.7M last year »

Reports Q1 Aristada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

FCN

FTI Consulting

$78.95

-0.04 (-0.05%)

07:40
04/25/19
04/25
07:40
04/25/19
07:40
Earnings
FTI Consulting backs FY19 adj. EPS view $3.50-$4.00, consensus $3.71 »

Backs FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 29

    Apr

RRC

Range Resources

$9.76

0.08 (0.83%)

07:39
04/25/19
04/25
07:39
04/25/19
07:39
Downgrade
Range Resources rating change  »

Range Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 22

    May

SWK

Stanley Black & Decker

$145.79

-1.58 (-1.07%)

07:38
04/25/19
04/25
07:38
04/25/19
07:38
Recommendations
Stanley Black & Decker analyst commentary  »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 16

    May

FCN

FTI Consulting

$78.95

-0.04 (-0.05%)

07:37
04/25/19
04/25
07:37
04/25/19
07:37
Earnings
FTI Consulting reports Q1 adj. EPS $1.63, consensus 99c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 29

    Apr

NCI

Navigant Consulting

$21.00

0.38 (1.84%)

07:37
04/25/19
04/25
07:37
04/25/19
07:37
Earnings
Navigant Consulting backs FY19 adjusted EPS view 85c-$1.00, consensus 89c »

Backs FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 23

    May

  • 28

    May

SAH

Sonic Automotive

$15.84

0.45 (2.92%)

07:36
04/25/19
04/25
07:36
04/25/19
07:36
Earnings
Sonic Automotive reports Q1 adjusted EPS 39c, consensus 23c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 13

    Nov

TSLA

Tesla

$258.70

-5.15 (-1.95%)

07:36
04/25/19
04/25
07:36
04/25/19
07:36
Recommendations
Tesla analyst commentary  »

Tesla seems less opposed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BWB

Bridgewater Bancshares

$10.53

-0.07 (-0.66%)

07:36
04/25/19
04/25
07:36
04/25/19
07:36
Earnings
Bridgewater Bancshares reports Q1 EPS 23c, consensus 24c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$182.64

-1.13 (-0.61%)

07:36
04/25/19
04/25
07:36
04/25/19
07:36
Recommendations
Facebook analyst commentary at Morgan Stanley »

Facebook price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 03

    Jun

NCI

Navigant Consulting

$21.00

0.38 (1.84%)

07:35
04/25/19
04/25
07:35
04/25/19
07:35
Hot Stocks
Navigant Consulting CEO says 'poised to deliver' 2019 cont ops. guidance targets »

CEO Julie Howard said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 23

    May

  • 28

    May

NOW

ServiceNow

$242.41

-1.085 (-0.45%)

07:35
04/25/19
04/25
07:35
04/25/19
07:35
Recommendations
ServiceNow analyst commentary  »

ServiceNow price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    May

WAB

Wabtec

$76.57

-0.19 (-0.25%)

07:35
04/25/19
04/25
07:35
04/25/19
07:35
Earnings
Wabtec backs FY19 adj. EPS view $4.00-$4.20, consensus $4.15 »

Backs FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 21

    May

  • 05

    Jun

  • 13

    Nov

FB

Facebook

$182.64

-1.13 (-0.61%)

, CVE

Cenovus Energy

$10.19

-0.25 (-2.39%)

07:35
04/25/19
04/25
07:35
04/25/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

FB

Facebook

$182.64

-1.13 (-0.61%)

CVE

Cenovus Energy

$10.19

-0.25 (-2.39%)

AMRN

Amarin

$18.47

0.08 (0.44%)

ORCL

Oracle

$55.17

0.23 (0.42%)

OXY

Occidental Petroleum

$62.00

-0.35 (-0.56%)

COP

ConocoPhillips

$64.71

-1.74 (-2.62%)

JNPR

Juniper

$28.73

0.355 (1.25%)

IVZ

Invesco

$21.53

-0.09 (-0.42%)

CSIQ

Canadian Solar

$20.17

-0.085 (-0.42%)

CNSL

Consolidated Communications

$8.89

-0.03 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 28

    Apr

  • 29

    Apr

  • 30

    Apr

  • 01

    May

  • 06

    May

  • 07

    May

  • 08

    May

  • 10

    May

  • 14

    May

  • 14

    May

  • 22

    May

  • 29

    May

  • 30

    May

  • 03

    Jun

NCI

Navigant Consulting

$21.00

0.38 (1.84%)

07:34
04/25/19
04/25
07:34
04/25/19
07:34
Earnings
Navigant Consulting reports Q1 adjusted EPS 18c, consensus 8c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 23

    May

  • 28

    May

ADS

Alliance Data

$163.54

0.47 (0.29%)

07:34
04/25/19
04/25
07:34
04/25/19
07:34
Earnings
Alliance Data lowers FY19 core EPS view to $18.47 from $22.00, consensus $21.82 »

Lowers FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 05

    Jun

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.